|
|
Vioxx Recall: The
international prescription drug company
Merck announced in September 2004 the worldwide
withdrawal of the arthritis medication Rofecoxib,
sold in most countries under the brand name
Vioxx, because a study showed an increased
risk of heart attack and stroke.
Vioxx
Trial: Patients
who have suffered injuries due to Vioxx
have filed litigation against Merck for
selling Vioxx even though Merck allegedly
was aware of Vioxx's dangerous
side effects. |
|
|
|
| |
|
Vioxx
Dangers, Vioxx Recall
and Vioxx Suit
|
|
| |
|
- Early
2001: FDA Meets To Discuss Findings
At a meeting of an FDA advisory panel, Merck
argues that the trial results might reflect the protective
effects of naproxen and not danger from its drug.
The committee ends up recommending that the issue
be noted on Vioxx's label, and members call for follow-up
research to clear up the questions.
- February
2001: FDA Approves Vioxx Re-Labeling
FDA Approves Merck request to label Vioxx as safer
on the stomach than older painkillers, giving the
drug a slight but important edge over Celebrex.
- August
2001: Further Examination of Vioxx Adverse
Effects Published
Doctors at the Cleveland Clinic examine data from
several trials of Vioxx patients and publish their
findings in the Journal of
the American Medical Association, claiming the “available data raise
a cautionary flag about the risk of cardiovascular
events"
with Cox-2 inhibitors, especially Vioxx.
- September
17, 2001: FDA Letter Warns Merck on Advertising
and Vioxx Side Effects
In an eight-page letter to Merck Chief Executive
Raymond Gilmartin, the FDA warns Merck for engaging
"in a promotional campaign for Vioxx that minimizes
the potentially serious cardiovascular findings that
were observed" in a clinical trial comparing
Vioxx to naproxen, a less-expensive painkiller. "Your
promotional campaign discounts the fact" that
in the trial, "patients on Vioxx were observed
to have a four to five-fold increase" in heart
attacks, compared with patients on naproxen, the letter
said.
- April
2002: FDA Approves New Vioxx Labeling
The FDA, following up on the advisory panel's
advice from the year before, approves new labeling
for Vioxx that points out the association with higher
heart-attack and stroke risk.
- 2003:
High Volume of Vioxx Sales
Worldwide sales of Vioxx reach $2.5 billion.
- October
2003: Merck Study Finds Increased Vioxx Risk
Merck-funded study finds patients taking Vioxx are
at a 39% increased risk of heart attack within the
first ninety days, compared with Celebrex.
|
| |
|
|
|
| Lieff Cabraser: Experienced Product Liability Lawyers |
| Founded in 1972, Lieff Cabraser Heimann & Bernstein,
LLP is an over fifty attorney law firm with offices in San Francisco, New
York and Nashville. For the last five years, the National Law Journal has
recognized Lieff Cabraser as one of the top plaintiffs’ law firms
in America. |
| For our personal injury cases, we bring a team of experienced lawyers. Each client is assigned a partner and an associate. In addition, we have on staff multiple nurses, legal assistants, scientific analysts and case clerks to assist the attorneys. |
| We have represented thousands of patients who ingested prescription drugs with dangerous undisclosed side effects, and patients who received defective medical devices in personal injury lawsuits across America, including residents of Alaska, Alabama, Arkansas, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Maryland, Maine, Michigan, Minnesota, Missouri, Montana, North Carolina, North Dakota, Nebraska, New Hampshire, New Jersey, New Mexico, Nevada, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Utah, Virginia, Vermont, Washington, Wisconsin, West Virginia and Wyoming. |
|
|
|
|
|
Lieff
Cabraser Heimann & Bernstein, LLP
|
|
|
|
|
|
|
| Trademark Notice |
| "Vioxx" is
a registered trademark of Merck. Lieff Cabraser Heimann & Bernstein,
LLP is in no way affiliated with Merck, and the Vioxx
trademark is used solely for informational purposes. |
|
|
|
Copyright © 2007 Lieff Cabraser Heimann & Bernstein, LLP |
| |
|
|
Merck
Agrees to Resolve U.S. VIOXX® Product
Liability Lawsuits
November 9, 2007
Merck & Co., Inc.
announced that
it has entered into
an agreement to resolve
state and federal myocardial
infarction (MI) and
ischemic stroke claims
already filed against
the Company in the
United States. More... |
|
|
|
|